Gainers
- Venus Concept (NASDAQ:VERO) shares rose 129.5% to $6.61 during Tuesday's after-market session. The market value of their outstanding shares is at $4.3 million.
- SCWorx (NASDAQ:WORX) shares moved upwards by 60.8% to $1.28. The market value of their outstanding shares is at $2.6 million.
- Salarius Pharmaceuticals (NASDAQ:SLRX) shares increased by 34.26% to $1.09. The company's market cap stands at $1.8 million.
- NAYA Biosciences (NASDAQ:NAYA) shares moved upwards by 13.98% to $2.2. The market value of their outstanding shares is at $10.8 million.
- Aethlon Medical (NASDAQ:AEMD) stock moved upwards by 12.12% to $0.37. The company's market cap stands at $7.6 million.
- Anixa Biosciences (NASDAQ:ANIX) shares moved upwards by 10.88% to $2.63. The market value of their outstanding shares is at $84.6 million.
Losers
- Vincerx Pharma (NASDAQ:VINC) stock declined by 55.6% to $0.24 during Tuesday's after-market session.
- NanoVibronix (NASDAQ:NAOV) shares declined by 14.31% to $6.11. The market value of their outstanding shares is at $4.6 million.
- Protagenic Therapeutics (NASDAQ:PTIX) shares fell 12.69% to $0.24. The company's market cap stands at $1.8 million.
- 180 Life Sciences (NASDAQ:ATNF) stock declined by 12.26% to $0.62. The market value of their outstanding shares is at $2.4 million.
- Revelation Biosciences (NASDAQ:REVB) stock declined by 11.39% to $3.27. The company's market cap stands at $2.9 million.
- ABVC BioPharma (NASDAQ:ABVC) stock decreased by 8.36% to $0.82. The company's market cap stands at $19.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
AEMDAethlon Medical Inc
$5.23-3.68%
ANIXAnixa Biosciences Inc
$4.121.48%
NAOVNanoVibronix Inc
$5.31-%
PTIXProtagenic Therapeutics Inc
$2.501.28%
REVBRevelation Biosciences Inc
$1.23-1.58%
SLRXSalarius Pharmaceuticals Inc
$3.891.30%
VEROVenus Concept Inc
$2.130.95%
VINCVincerx Pharma Inc
$0.00550-94.5%
WORXSCWorx Corp
$0.3088-7.24%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
